Congress funds cancer screening for uninsured women through 2030

What it does

This bill reauthorizes and expands the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), a federal program that has provided free or low-cost cancer screening to uninsured and underinsured women since 1991. The bill funds the program at $235 million annually through 2030, adds new requirements to reduce health disparities and improve equitable access to screening services, and mandates a Government Accountability Office study to assess program reach and barriers to care.

Why we flagged it

The bill's core function is straightforward: reauthorize and fund an existing federal cancer screening program for vulnerable populations, with explicit additions to address health equity and disparities. This is routine public health legislation without hidden mechanisms or narrow beneficiaries.

What the text implies

• Explicit focus on reducing disparities and removing barriers may require states to implement new outreach and care-coordination infrastructure, potentially increasing administrative burden on state health departments.
• Requirement for evidence-based screening strategies and health care navigation services may indirectly increase demand for clinical staff and patient-navigation roles in underserved areas.
• GAO study requirement (due Sept 2027) will generate data on program reach and barriers; findings could inform future expansions or identify systemic gaps in cancer screening access.

Who it affects

The bill expands access to preventive cancer screening for low-income and underinsured women, populations with historically lower screening rates and higher mortality. Early detection of breast and cervical cancer significantly improves treatment outcomes and survival; the program has already diagnosed nearly 80,000 invasive breast cancers and over 5,300 cervical cancers. Dedicated funding and explicit focus on reducing disparities and removing barriers directly benefits vulnerable populations.

Who stands to gain

• state health departments (program administration)
• federally qualified health centers (screening service providers)
• patient navigation and care coordination service providers
• diagnostic imaging and pathology labs (increased screening volume)

Named in the bill

National Breast and Cervical Cancer Early Detection Program (NBCCEDP), Public Health Service Act, Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce, Government Accountability Office (GAO), Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

8 cosponsors: 5 Democrats, 3 Republicans.

• May 22, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• May 22, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $520,000 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Tammy Baldwin, the sponsor, reported $195,336 in PAC receipts in the 2026 cycle. $4,500 of that came from 2 PACs tied to these lobbying clients.

• GE Healthcare Technologies Inc. — $350,000 on 1 filing
• The Susan G. Komen Breast Cancer Foundation, Inc. Dba Susan G. Komen — $130,000 on 1 filing
• Susan G. Komen — $40,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.